SOUTH SAN FRANCISCO--(BUSINESS WIRE)-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform ...

Conclusion Untreated or undiagnosed adjustment disorder is like a silent storm brewing within an individual's life. At first, it may seem manageable, just a few raindrops of stress or anxiety that ...

Topline results of the exploratory Phase 2 clinical study anticipated in Q1 2023 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company ...

A Study on the Intervention Effect of Emotion-Focused Therapy in Adolescent Adjustment Disorder. Psychology, 16, 1097-1104.

Upsized Series A Financing Brings Total Amount Raised to $133 Million -- -- GAD Affects 3.1% of U.S. Adult Population; Minority of Patients Receive Treatment -- -- Reunion Expects to Initiate RECLAIM ...

Adjustment disorder is a mental health condition where a person develops emotional or behavioural symptoms in response to a stressor. The biotech will also use the proceeds to push RE104, a prodrug of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, ...